Move to topTop
May 01, 2017

Lakewood, Colo., USA - May 1, 2017 - Terumo BCT, a global medical device manufacturing company, announced today that a team from the Aarhus University Hospital (AUH) in Denmark led by Anna-Marie Eller Thomsen is the winner of the 2016 Advancing Apheresis Award: Solving Venous Access Challenges. This marks the first time an all-nurse team has won the award. They plan to use the funds to host educational events building on their success in implementing and performing peripheral ultrasound-guided vascular access (PUGVA) for apheresis procedures.

"We are honored to win the Advancing Apheresis Award, and we thank the Committee and Terumo BCT for recognizing our commitment to continually improving safety and care for our patients. This opportunity expands our ability to optimize our use of peripheral ultrasound-guided vascular access and to educate others, and it helps in our goal to be among the leading apheresis centers in the world," said Anna-Marie Eller Thomsen.

In its fourth year, the Terumo BCT Advancing Apheresis Award is part of a long-term commitment to support those who improve patient care in the use of therapeutic apheresis and cell collections. Each year, the winner is chosen by an external, global committee of key opinion leaders. Their decision included considerations for AUHs plans for use of the award, its history of demonstrating educational leadership and its impact to the community. The 2016 Terumo BCT Grant Committee included:

  • Prof. Franz Schaefer, MD
    • Pediatric Nephrology, University of Heidelberg, Germany
    • Paolo Malvezzi, MD
      • Nephrology & Transplantation, Centre Hospitalier Universitaire, Grenoble, France
      • Sheryl McDiarmid, RN, BScN, MEd, MBA
        • Vascular Access Program Founder, Ottawa Hospital, Canada
        • Ed Harris, MS, Patient Advocate
          • Executive Director, Scleroderma Education Project, Madison, WI, USA

          Each year, the Advancing Apheresis Award features a different emphasis. For 2016, it focused on solving venous access challenges. "Selecting and securing the appropriate approach to vascular access is a challenge; improving peripheral access can lead to improved patient and clinical experience. We are privileged to honor the efforts of clinicians, physicians and operators who continue to enhance patient experience and outcomes around the world," said Monte Smith, Vice President, Global Therapeutic Systems, Terumo BCT.

          For the first time in the history of the Advancing Apheresis Award, Terumo BCT included a patient advocate on the review committee. Ed Harris currently serves as Executive Director and Research Fellow in the department of Medical Microbiology and Immunology at the University of Wisconsin-Madison. Mr. Harris has been a patient in over 365 therapeutic apheresis procedures, all performed with peripheral venous access.

          Terumo BCT is now seeking applications for the 2017 Award: Bringing Perspective to Cell Collections for Immunotherapy. The program is open to apheresis professionals, clinicians, researchers, and cell, gene and immunotherapy developers from around the world.

          Key Dates

          May 1, 2017 Applications Accepted
          September 30, 2017 Application Deadline
          November 2017 Award Winner Announcement

          About Terumo BCT

          Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction technologies. We believe in the potential of blood to do even more for patients than it does today. This belief inspires our innovation and strengthens our collaboration with customers.

          About Terumo

          Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

          Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.


          Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.